{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["40(3)"],"submitter":["Ito S"],"funding":["Daiichi-Sankyo"],"pubmed_abstract":["<h4>Introduction</h4>This study investigated factors associated with the antihypertensive effects of esaxerenone and the incidence of serum potassium elevation in patients with hypertension.<h4>Methods</h4>Using pooled data from seven phase III studies, the study analyzed factors associated with changes in office systolic (SBP) and diastolic (DBP) blood pressure from baseline to 12 weeks, and factors associated with incidence of serum potassium levels ≥ 5.5 mEq/L in esaxerenone-treated patients.<h4>Results</h4>Overall, 1466 and 1472 patients were included in the full analysis and safety analysis sets, respectively. Male sex (4.02/2.40 mmHg), weight ≥ 78.4 kg (4.62/2.09 mmHg), hypertension duration ≥ 10 years (2.66/1.71 mmHg), prior antihypertensive treatment (2.38/1.40 mmHg), plasma aldost"],"journal":["Advances in therapy"],"pagination":["1242-1266"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9988784"],"repository":["biostudies-literature"],"pubmed_title":["Factors Associated with the Antihypertensive Effect of Esaxerenone and Serum Potassium Elevation: A Pooled Analysis of Seven Phase III Studies."],"pmcid":["PMC9988784"],"pubmed_authors":["Ito S","Sugimoto K","Okuda Y"],"additional_accession":[]},"is_claimable":false,"name":"Factors Associated with the Antihypertensive Effect of Esaxerenone and Serum Potassium Elevation: A Pooled Analysis of Seven Phase III Studies.","description":"<h4>Introduction</h4>This study investigated factors associated with the antihypertensive effects of esaxerenone and the incidence of serum potassium elevation in patients with hypertension.<h4>Methods</h4>Using pooled data from seven phase III studies, the study analyzed factors associated with changes in office systolic (SBP) and diastolic (DBP) blood pressure from baseline to 12 weeks, and factors associated with incidence of serum potassium levels ≥ 5.5 mEq/L in esaxerenone-treated patients.<h4>Results</h4>Overall, 1466 and 1472 patients were included in the full analysis and safety analysis sets, respectively. Male sex (4.02/2.40 mmHg), weight ≥ 78.4 kg (4.62/2.09 mmHg), hypertension duration ≥ 10 years (2.66/1.71 mmHg), prior antihypertensive treatment (2.38/1.40 mmHg), plasma aldost","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-04-21T19:48:02.336Z","creation":"2025-04-05T17:43:27.962Z"},"accession":"S-EPMC9988784","cross_references":{"pubmed":["36662393"],"doi":["10.1007/s12325-022-02393-x"]}}